A citation-based method for searching scientific literature

Ele Ferrannini, Michael Mark, Eric Mayoux. Diabetes Care 2016
Times Cited: 502



Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
Times Cited: 622




List of shared articles



Times cited

Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors.
Mohammad Shafi Kuchay, Khalid Jamal Farooqui, Sunil Kumar Mishra, Ambrish Mithal. Adv Exp Med Biol 2021
4



Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.
Adriana Marton, Tatsuroh Kaneko, Jean-Paul Kovalik, Atsutaka Yasui, Akira Nishiyama, Kento Kitada, Jens Titze. Nat Rev Nephrol 2021
17

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Emily Brown, John P H Wilding, Uazman Alam, Thomas M Barber, Janaka Karalliedde, Daniel J Cuthbertson. Ann Med 2021
2

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
12

Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition.
Peter Wolf, Paul Fellinger, Lorenz Pfleger, Hannes Beiglböck, Patrik Krumpolec, Chiara Barbieri, Amalia Gastaldelli, Jürgen Harreiter, Matthäus Metz, Thomas Scherer,[...]. Diabetes Care 2021
0

SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
Maja Nikolic, Vladimir Zivkovic, Jovana Joksimovic Jovic, Jasmina Sretenovic, Goran Davidovic, Stefan Simovic, Danijela Djokovic, Nemanja Muric, Sergey Bolevich, Vladimir Jakovljevic. Heart Fail Rev 2021
6

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
17

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
B Gaborit, P Ancel, A E Abdullah, F Maurice, I Abdesselam, A Calen, A Soghomonian, M Houssays, I Varlet, M Eisinger,[...]. Cardiovasc Diabetol 2021
3

SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.
Xiaodan Wang, Jingyu Ni, Rui Guo, Lan Li, Jing Su, Feng He, Guanwei Fan. Heart Fail Rev 2021
0

Unexpected Pleiotropic Effects of SGLT2 Inhibitors: Pearls and Pitfalls of This Novel Antidiabetic Class.
Hideaki Kaneto, Atsushi Obata, Tomohiko Kimura, Masashi Shimoda, Tomoe Kinoshita, Taka-Aki Matsuoka, Kohei Kaku. Int J Mol Sci 2021
1


Paradigm shift in heart failure treatment: are cardiologists ready to use gliflozins?
Michele Correale, Renata Petroni, Stefano Coiro, Elena-Laura Antohi, Francesco Monitillo, Marta Leone, Marco Triggiani, Shiro Ishihara, Hans-Dirk Dungen, Chaudhry M S Sarwar,[...]. Heart Fail Rev 2021
0

Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
Utkarsh Ojha, Lenisse Reyes, Florence Eyenga, Diane Oumbe, Justyna Watkowska, Henock Saint-Jacques. Am J Cardiovasc Drugs 2021
2

Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes.
Hongyan Liu, Vikas S Sridhar, Daniel Montemayor, Leif Erik Lovblom, Yuliya Lytvyn, Hongping Ye, Jiwan Kim, Mir Tariq Ali, Daniel Scarr, Patrick R Lawler,[...]. Diabetes Obes Metab 2021
0

Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms.
Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang. Cardiovasc Drugs Ther 2021
1

Case of sodium-glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis.
Huei Li Yeoh, Marilyn Lee, Woei Jack Pan, Hean Yee Ong. BMJ Case Rep 2021
0